Oxalic Acid

Oxalic Acid

SCHEMBL6892216

O=C(O)C(=O)O.O=c1[nH]cccc1CN1CCC(CCc2ccccc2OC2CCCC2)CC1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
KCNH2 Q12809 1/20 0.39
S1PR5 Q9H228 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL5780721 0.88 KCNH2 (0.42) MEN1KMT2AKDM4EKCNH2MAPT
Oxalic Acid SCHEMBL5782385 0.87 KDM4E (0.44) MEN1KMT2AALDH1A1KDM4EDRD2
Oxalic Acid SCHEMBL6896125 0.87 KCNH2 (0.41) MEN1KMT2AALDH1A1KDM4EKCNH2
Oxalic Acid SCHEMBL5777380 0.87 KCNH2 (0.41) MEN1KMT2AALDH1A1KDM4EKCNH2
Oxalic Acid SCHEMBL6893599 0.87 CHRM4 (0.45) MEN1KMT2AKCNH2POLB
Oxalic Acid SCHEMBL5781973 0.86 EPHX2 (0.45) KCNH2
Oxalic Acid SCHEMBL5779827 0.85 KCNH2 (0.47) MEN1KMT2AKCNH2DRD2DRD4
Oxalic Acid SCHEMBL5781614 0.84 KCNH2 (0.53) MEN1KMT2AALDH1A1KDM4EKCNH2
Oxalic Acid SCHEMBL5779534 0.84 OPRK1 (0.43) KCNH2DRD2DRD4DRD3
Oxalic Acid SCHEMBL6888474 0.83 KCNH2 (0.47) MEN1KMT2AKDM4EKCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784192-B2 NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC EISAI CO., LTD. (JP) 2004-08-31 US disclosed
US-20030220368-A1 Novel piperidine compouds and drugs containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-11-27 US disclosed
EP-1254904-A1 NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220368-A1 Novel piperidine compouds and drugs containing the same TRPV1, CACNA1D, KCND2 MEN1 3216/4885KMT2A 1308/4885ALDH1A1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.